In the same year, we added to the system an antibody against transferrin receptor as a targeting moiety, demonstrating in vitro, using tumor spheroids, that the targeting was improved and transcytosis from endothelial cells to the spheroids occurred. This evidence concerns the gene TFRC and neoplasm.